Engineering Multienzyme-Mimicking Covalent Organic Frameworks as Pyroptosis Inducers for Boosting Antitumor Immunity

Engineering Multienzyme-Mimicking Covalent Organic Frameworks as Pyroptosis Inducers for Boosting Antitumor Immunity

© 2022 Wiley-VCH GmbH.

Détails bibliographiques
Publié dans:Advanced materials (Deerfield Beach, Fla.). - 1998. - 34(2022), 13 vom: 15. Apr., Seite e2108174
Auteur principal: Zhang, Liang (Auteur)
Autres auteurs: Yang, Qi-Chao, Wang, Shuo, Xiao, Yao, Wan, Shu-Cheng, Deng, Hexiang, Sun, Zhi-Jun
Format: Article en ligne
Langue:English
Publié: 2022
Accès à la collection:Advanced materials (Deerfield Beach, Fla.)
Sujets:Journal Article cancer immune therapy chemodynamic therapy covalent organic frameworks pyroptosis Metal-Organic Frameworks
Description
Résumé:© 2022 Wiley-VCH GmbH.
The engineering of a series of multienzyme-mimicking covalent organic frameworks (COFs), COF-909-Cu, COF-909-Fe, and COF-909-Ni, as pyroptosis inducers, remodeling the tumor microenvironment to boost cancer immunotherapy, is reported. Mechanistic studies reveal that these COFs can serve as hydrogen peroxide (H2 O2 ) homeostasis disruptors to elevate intracellular H2 O2 levels, and they not only exhibit excellent superoxide dismutase (SOD)-mimicking activity and convert superoxide radicals (O2 •- ) to H2 O2 to facilitate H2 O2 generation, but also possess outstanding glutathione peroxidase (GPx)-mimicking activity and deplete glutathione (GSH) to alleviate the scavenging of H2 O2 . Meanwhile, the outstanding photothermal therapy properties of these COFs can accelerate the Fenton-like ionization process to facilitate their chemodynamic therapy efficiency. One member, COF-909-Cu, can robustly induce gasdermin E (GSDME)-dependent pyroptosis and remodel the tumor microenvironment to trigger durable antitumor immunity, thus promoting the response rate of αPD-1 checkpoint blockade and successfully restraining tumor metastasis and recurrence
Description:Date Completed 04.04.2022
Date Revised 29.08.2024
published: Print-Electronic
ErratumIn: Adv Mater. 2024 Oct;36(40):e2411797. doi: 10.1002/adma.202411797. - PMID 39206594
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202108174